Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus DOCIVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus DOCIVYX.
CEFOTETAN vs DOCIVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
75 mg/m2 intravenously over 1 hour every 3 weeks.
None Documented
None Documented
3-4.5 hours (6-8 hours in renal impairment).
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."
Clinical Note
moderateCefotetan + Carbocisteine
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine."